Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026
- Press release covers recent corporate developments and results
- Conference call and webcast provide management commentary
- Detailed financial figures and outlook available in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 contains the substantive Regulation FD disclosure and is the key document for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $180.3M, up 13% YoY, led by ORLADEYO revenue of $174.8M
- GAAP operating profit $53.3M, up from $29.6M, with non-GAAP operating profit $86.5M
- Total 2026 revenue guidance increased to $715M-$730M, while ORLADEYO guidance remained $625M-$645M
- Non-GAAP operating expense guidance improved to $415M-$425M, supporting profitability and cash generation
- FDA approval of ORLADEYO pellets for patients aged 12 and older expands formulation access; Birmingham closure targets $30M-$35M annualized savings after approximately $10M cash costs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.